Trilaciclib

Generic Name: Trilaciclib

Brand Names: Cosela

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₀N_₈O

CAS Number: 1374743-00-6

Unique Ingredient Identifier: U6072DO9XG

Background: Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer. CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis...

Indication: Trilaciclib is indicated to reduce the incidence of chemotherapy induced myelosuppression in patients prior to receiving platinum and etoposide-containing or topotecan-containing chemotherapy regimens for extensive-stage small cell lung cancer.

Associated Conditions: Bone Marrow Suppression caused by Chemotherapy

Associated Therapies: -

Clinical Trials

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions: Drug: Trilaciclib

First Posted Date: 2024-12-03

Last Posted Date: 2024-12-03

Lead Sponsor: Shandong Cancer Hospital and Institute

Target Recruit Count: 30

Registration Number: NCT06714266

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Phase 2

Recruiting

Conditions: Osteosarcoma

Interventions: Drug: Trilaciclib
Drug: Pirarubicin
Drug: Lobaplatin

First Posted Date: 2024-12-03

Last Posted Date: 2024-12-03

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 50

Registration Number: NCT06714383

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin

Phase 2

Recruiting

Conditions: Lung Cancer, Small Cell

Interventions: Drug: Chemotherapy （Etoposide and Carboplatin）
Drug: Immunotherapy （Envafolimab）
Drug: Trilaciclib

First Posted Date: 2024-11-21

Last Posted Date: 2024-11-21

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 52

Registration Number: NCT06698965

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Phase 2

Conditions: Myelosuppression

Interventions: Drug: Trilaciclib

First Posted Date: 2024-07-08

Last Posted Date: 2024-07-16

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT06490081

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Phase 2

Not yet recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Trilaciclib

First Posted Date: 2024-04-17

Last Posted Date: 2024-04-17

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT06370416

Locations: 🇨🇳
Henan Tumor Hospital, Zhengzhou, Henan, China

Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma

Phase 2

Not yet recruiting

Conditions: Osteosarcoma

Interventions: Drug: Trilaciclib

First Posted Date: 2024-01-22

Last Posted Date: 2024-01-22

Lead Sponsor: The First Affiliated Hospital of Xinxiang Medical College

Target Recruit Count: 20

Registration Number: NCT06217003

Locations: 🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

Phase 2

Recruiting

Conditions: Metastatic Triple-Negative Breast Cancer

Interventions: Drug: Trilaciclib
Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2023-09-07

Last Posted Date: 2024-07-18

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 36

Registration Number: NCT06027268

Locations: 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy

Phase 2

Recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Trilaciclib
Drug: Epirubicin
Drug: Docetaxel
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Paclitaxel
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2023-08-07

Last Posted Date: 2023-11-30

Lead Sponsor: wang shusen

Target Recruit Count: 116

Registration Number: NCT05978648

Locations: 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Gangdong, China

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Advanced Squamous Non-Small-Cell Lung Cancer

Interventions: Drug: Trilaciclib
Drug: Carboplatin
Drug: Paclitaxel
Drug: Tislelizumab

First Posted Date: 2023-06-13

Last Posted Date: 2023-06-13

Lead Sponsor: Sichuan University

Target Recruit Count: 132

Registration Number: NCT05900921

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Phase 4

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: Placebo
Drug: Trilaciclib
Drug: Topotecan

First Posted Date: 2023-05-24

Last Posted Date: 2023-11-07

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 302

Registration Number: NCT05874401

Locations: 🇧🇪
CHU de Liège, Liege, Belgium
🇧🇪
Centre Hospitalier de l'Ardenne, Libramont, Belgium
🇵🇱
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Poland

and more 53 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy